Current Management and Novel Approaches to the Management of Follicular Lymphoma

  • Jonathon B. Cohen
  • Brad S. KahlEmail author


Fortunately, most patients with advanced-stage follicular lymphoma will enjoy prolonged overall survival and can be managed with nonintensive systemic therapy. However, the determination of the timing of initiation of therapy and which treatment should be used remains challenging in the modern era. While most patients who complete induction therapy will remain in remission for several years and can expect survival to be similar to age-matched controls, up to 20% of patients with follicular lymphoma will experience relapse within 24 months, portending a poor prognosis and inferior survival. In this chapter, we will review the utility of watchful waiting in patients with low tumor burden, current approaches to induction therapy, and the potential use of post-induction treatments including rituximab maintenance. We will discuss current investigations designed to explore novel therapies, improve outcomes, and limit toxicities. We will discuss long-term impacts of treatment, including the development of secondary malignancies, which is critical in this disease that is associated with a prolonged survival.


Follicular lymphoma Indolent lymphoma Non-Hodgkin lymphoma Chemotherapy Risk stratification Maintenance therapy Toxicities of treatment Disease surveillance Investigational treatment Targeted therapies 


  1. 1.
    Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med. 1984;311(23):1471–5.CrossRefGoogle Scholar
  2. 2.
    Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997;15(3):1110–7.CrossRefGoogle Scholar
  3. 3.
    Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol. 1988;25(2 Suppl 2):11–6.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet. 2003;362(9383):516–22.CrossRefGoogle Scholar
  5. 5.
    Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial. Lancet Oncol. 2014;15(4):424–35.CrossRefGoogle Scholar
  6. 6.
    Kahl BS, Hong F, Williams ME, Gascoyne RD, Wagner LI, Krauss JC, et al. Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402. J Clin Oncol. 2014;32(28):3096–102.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Wagner LI, Zhao F, Hong F, Williams ME, Gascoyne RD, Krauss JC, et al. Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT). J Clin Oncol. 2015;33(7):740–8.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104(5):1258–65.CrossRefGoogle Scholar
  9. 9.
    Evens AM, Hong F, Habermann TM, Advani RH, Gascoyne RD, Witzig TE, et al. A 3-arm randomized phase II trial with bendamustine/rituximab therapy in untreated high risk (HR) follicular lymphoma (FL): bortezomib induction or novel IMiD<sup>®</sup> continuation (BIONIC) study from the ECOG-ACRIN Cancer Research Group. Blood. 2017;130(Suppl 1):482.Google Scholar
  10. 10.
    Blum KA, Jung S-H, Barak I, Hsi ED, Wagner-Johnston ND, Christian B, et al. Randomized phase 2 trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib induction and maintenance therapy in patients (pts) with previously untreated high risk follicular lymphoma (FL): results from CALGB 50904 (Alliance). Blood. 2017;130(Suppl 1):485.Google Scholar
  11. 11.
    Kahl BS. Follicular lymphoma: are we ready for a risk-adapted approach? ASH Education Program Book. 2017;2017(1):358–64.Google Scholar
  12. 12.
    Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, et al. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol. 2009;27(8):1202–8.PubMedPubMedCentralCrossRefGoogle Scholar
  13. 13.
    Federico M, Luminari S, Dondi A, Tucci A, Vitolo U, Rigacci L, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013;31(12):1506–13.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Luminari S, Ferrari A, Manni M, Dondi A, Chiarenza A, Merli F, et al. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. J Clin Oncol. 2017:JCO2017741652.Google Scholar
  15. 15.
    Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, Macdonald D, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood. 2014;123(19):2944–52.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grunhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–10.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Rummel MJ, Maschmeyer G, Ganser A, Heider A, Uv G, Losem C, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: nine-year updated results from the StiL NHL1 study. J Clin Oncol. 2017;35(15_suppl):7501.CrossRefGoogle Scholar
  18. 18.
    Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106(12):3725–32.CrossRefGoogle Scholar
  19. 19.
    Marcus R, Imrie K, Solal-Celigny P, Catalano JV, Dmoszynska A, Raposo JC, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26(28):4579–86.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–44.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, et al. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. Br J Haematol. 2012;157(4):438–45.PubMedCrossRefPubMedCentralGoogle Scholar
  22. 22.
    Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, et al. Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol. 2015;94(4):633–41.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Martin P, Jung SH, Pitcher B, Bartlett NL, Blum KA, Shea T, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol. 2017;28(11):2806–12.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014;15(12):1311–8.PubMedPubMedCentralCrossRefGoogle Scholar
  25. 25.
    Bartlett NL, Costello BA, LaPlant BR, Ansell SM, Kuruvilla JG, Reeder CB, et al. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. Blood. 2018;131(2):182–90. Scholar
  26. 26.
    Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen R, et al. Ibrutinib plus rituximab in treatment-naive patients with follicular lymphoma: results from a multicenter. Phase 2 Study Blood. 2015;126(23):470.Google Scholar
  27. 27.
    Ujjani CS, Jung SH, Pitcher B, Martin P, Park SI, Blum KA, et al. Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. Blood. 2016;128(21):2510–6.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Gopal AK, Kahl BS, de Vos S, Wagner-Johnston ND, Schuster SJ, Jurczak WJ, et al. PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014;370(11):1008–18.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, et al. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017;4(4):e176–e82.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    Cheah CY, Nastoupil LJ, Neelapu SS, Forbes SG, Oki Y, Fowler NH. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma. Blood. 2015;125(21):3357–9.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Greenwell IB, Ip A, Cohen JB. PI3K inhibitors: understanding toxicity mechanisms and management. Oncology. 2017;31(11):821–8.PubMedGoogle Scholar
  32. 32.
    Evens AM, Smith MR, Lossos IS, Helenowski I, Millenson M, Winter JN, et al. Frontline bortezomib and rituximab for the treatment of newly diagnosed high tumour burden indolent non-Hodgkin lymphoma: a multicentre phase II study. Br J Haematol. 2014;166(4):514–20.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Cohen JB, Switchenko JM, Koff JL, Sinha R, Kaufman JL, Khoury HJ, et al. A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma. Br J Haematol. 2015;171(4):539–46.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Thanarajasingam G, Atherton PJ, Novotny PJ, Loprinzi CL, Sloan JA, Grothey A. Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. Lancet Oncol. 2016;17(5):663–70.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–23.CrossRefGoogle Scholar
  36. 36.
    Hiddemann W, Barbui AM, Canales Albendea MA, Cannell PK, Collins GP, Dürig J, et al. Immunochemotherapy with obinutuzumab or rituximab in previously untreated follicular lymphoma in the randomised phase III gallium study: analysis by chemotherapy regimen. Hematolog Oncol. 2017;35:117–9.CrossRefGoogle Scholar
  37. 37.
    Fowler N, Nastoupil L, de Vos S, Knapp M, Flinn IW, Chen RW, et al. Ibrutinib combined with rituximab in treatment-naive patients with follicular lymphoma: arm 1 + arm 2 results from a multicenter, open-label phase 2 study. Blood. 2016;128(22):1804.CrossRefGoogle Scholar
  38. 38.
    Shi Q, Flowers CR, Hiddemann W, Marcus R, Herold M, Hagenbeek A, et al. Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials. J Clin Oncol. 2017;35(5):552–60.CrossRefGoogle Scholar
  39. 39.
    Casulo C, Le-Rademacher J, Dixon J, Salles G, Hoster E, Herold M, et al. Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials. Blood. 2017;130(Suppl 1):412.Google Scholar
  40. 40.
    Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, et al. Autologous transplantation in follicular lymphoma with early therapy failure: a NLCS and CIBMTR analysis. Biol Blood Marrow Transplant. 2018;24(6):1163–71. Epub 2017 Dec 11.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Hainsworth JD, Litchy S, Burris HA 3rd, Scullin DC Jr, Corso SW, Yardley DA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. J Clin Oncol. 2002;20(20):4261–7.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Hochster H, Weller E, Gascoyne RD, Habermann TM, Gordon LI, Ryan T, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 study. J Clin Oncol. 2009;27(10):1607–14.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Barta SK, Li H, Hochster HS, Hong F, Weller E, Gascoyne RD, et al. Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: a trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer. 2016;122(19):2996–3004.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Ghielmini M, Schmitz SF, Cogliatti SB, Pichert G, Hummerjohann J, Waltzer U, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103(12):4416–23.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Salles G, Seymour JF, Offner F, Lopez-Guillermo A, Belada D, Xerri L, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42–51.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D, et al. Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 years. Blood. 2017;130(Suppl 1):486.Google Scholar
  47. 47.
    Rummel MJ, Buske C, Hertenstein B, Lerchenmüller C, Koenigsmann M, Lange E, et al. Four versus two years of rituximab maintenance (R-maintenance) following bendamustine plus rituximab (B-R): initial results of a prospective, randomized multicenter phase 3 study in first-line follicular lymphoma (the StiL NHL7-2008 MAINTAIN study). Blood. 2017;130(Suppl 1):483.Google Scholar
  48. 48.
    Hill BT, Nastoupil L, Winter AM, Becnel MR, Cerhan JR, Habermann TM, et al. Maintenance rituximab or observation after frontline treatment with bendamustine-rituximab (BR) for follicular lymphoma: a real world analysis across 13 US cancer centers. Blood. 2017;130(Suppl 1):2779.Google Scholar
  49. 49.
    Kahl BS, Burke JM, van der Jagt R, Chang J, Wood P, Hawkins T, et al. Assessment of maintenance rituximab after first-line bendamustine-rituximab in patients with follicular lymphoma: an analysis from the BRIGHT trial. Blood. 2017;130(Suppl 1):484.Google Scholar
  50. 50.
    Kahl BS, Williams ME, Hong F, Gascoyne R, Horning SJ. Preliminary pharmacokinetic (PK) analysis of eastern cooperative oncology group protocol E4402: rituximab extended schedule or re-treatment trial (RESORT). Blood. 2007;110(11):3420.CrossRefGoogle Scholar
  51. 51.
    Nabhan C, Byrtek M, Rai A, Dawson K, Zhou X, Link BK, et al. Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. Br J Haematol. 2015;170(1):85–95.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010;10(4):270–7.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Goldman ML, Kim C, Chen Z, Calzada O, Churnetski MC, Flowers C, et al. Surveillance imaging during first-remission in follicular lymphoma does not impact overall survival. Blood. 2017;130(Suppl 1):1501.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Hematology and Medical OncologyEmory University – Winship Cancer InstituteAtlantaUSA
  2. 2.Department of Internal Medicine, Division of Medical OncologyWashington University School of Medicine – Siteman Cancer Center, Washington UniversitySt. LouisUSA

Personalised recommendations